Assessing dydrogesterone efficacy in endometrial protection for abnormal uterine bleeding from endometrial hyperplasia

This study was designed to determine the effectiveness of dydrogesterone in protecting the endometrium in females experiencing irregular uterine bleeding arising from endometrial hyperplasia. A cohort of 112 patients suffering from abnormal uterine bleeding due to endometrial hyperplasia, who underwent hysteroscopic surgery at our institution between January 2019 and May 2023, were assigned to two groups. Following the surgery, dydrogesterone was provided to the observation group. In contrast, medroxyprogesterone acetate-ethinyl estradiol tablets were utilized for the control group in conventional treatment. Primary outcomes included symptom improvement, treatment effectiveness, and safety profiles. Secondary outcomes involved assessing health-related life quality by employing the SF-36 questionnaire. The base characteristics were nearly the same between groups (P > 0.05). Following treatment, the observation group exhibited significantly greater improvements in symptoms and treatment effectiveness as opposed to the control group (P < 0.05), without an increase in adverse reactions. Moreover, while both groups experienced significant enhancements in SF-36 scores from baseline, the observation group showed more pronounced improvements in certain dimensions (P < 0.05). Dydrogesterone treatment following hysteroscopic surgery for females with abnormal uterine bleeding and endometrial hyperplasia demonstrates superior efficacy in endometrial protection and symptom management, without escalating adverse effects. The observed enhancements in quality of life underscore its clinical utility, suggesting dydrogesterone as a valuable therapeutic option in this clinical context.